Werewolf Therapeutics, Inc. (HOWL) intrinsic value & 10-year financials
Werewolf Therapeutics, Inc. (HOWL) has a Graham intrinsic value of $175.22 per share. At $0.98 on Oct 17, 2026, the stock trades 99% below that value. Over the last 7 fiscal years revenue shrank 80.6% a year to $0, with an average return on invested capital of -244.4%.
- Graham intrinsic value
- $175.22
- Share price (Oct 17, 2026)
- $0.98
- Price vs Graham value
- 99% below
- Market cap
- $45.9M
- Revenue (FY2025)
- $0
- Revenue growth (7-yr CAGR)
- -80.6%
- ROIC (10-yr avg)
- -244.4%
- Free cash flow (FY2025)
- —
HOWL 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $0 | -$60.8M | -$1.33 | — | — | -305.9% |
| FY2024 | $1.3M | -$70.5M | -$1.63 | -$56.4M | -5661.1% | -365.3% |
| FY2023 | $6.7M | -$37.4M | -$1.05 | -$33.4M | -604.5% | -185.4% |
| FY2022 | $0 | -$53.8M | -$1.86 | -$44.2M | — | -695.8% |
| FY2021 | $0 | -$50.0M | -$10.94 | -$43.4M | — | 75.3% |
| FY2020 | — | -$15.0M | -$1.56 | -$19.2M | — | 10.5% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Werewolf Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Werewolf Therapeutics, Inc. returns on capital have been average, hovering around 11.7% ROIC over the decade.
Werewolf Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Werewolf Therapeutics, Inc. is modeled at -80.6% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $175.22 per share.